CasNo.763113-22-0,Olaparib 763113-22-0 763113-22-0 C24H23FN4O3,(763113-22-0) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 98%
Payment Terms : D/A,T/T,

Keywords

Olaparib 763113-22-0 C24H23FN4O3

Quick Details

Appearance:detailed in specifcations
Application:API ,OLED .AND SO ON
PackAge:as needed
ProductionCapacity:20|Metric Ton|Month
Storage:cool place
Transportation:BY air or sea

Superiority:

Our Services

1.Certificate Of Analysis (COA)

2.Material Safety Data Sheet (MSDS)

3.Route of synthesis (ROS)

4.Method of Aanlysis (MOA)

5.Nuclear Magnetic Resonance (NMR)

6.Packing pictures and loading video before loading

7.Free Sample

9.Factory audit

10.Strong after-sale service

Company information

Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas.We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team.We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.

Details:

Olaparib Basic information

Therapeutic agent of ovarian cancer Pharmacological effects Pharmacokinetics Drug Interactions Adverse reactions

Product Name:	Olaparib
Synonyms:	Olaparib;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine;Olaparib(AZD-2281);Azd 2281;Azd2281;Azd-2281;Ku-0059436;4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Olaparib
CAS:	763113-22-0
MF:	C24H23FN4O3
MW:	434.469
EINECS:
Product Categories:	APIs;API;Inhibitor;Inhibitors
Mol File:	763113-22-0.mol

Olaparib Chemical Properties

density

1.43

Safety Information

HazardClass

IRRITANT

MSDS Information

Olaparib Usage And Synthesis

Therapeutic agent of ovarian cancer

Breast and ovarian cancer is a serious public health problem which is imposing severe threat on female. In recent years, the increasing rate of breast cancer incidence of China was even 1-2% higher than that of high- incidence countries. On the other hand, ovarian cancer still remains the most serious challenge for gynecologic oncologist because no mature approach for early stage diagnosis is available now. Upon diagnosis, about 70% cases are in advanced stage. Even subjecting to effective treatment and achieving complete alleviation, there are still 70% of patients who will get recurrence issue with 5-year survival rate hovering around 30-40%. Therefore, people are attempts to establish the three-level prevention and control measures of ovarian cancer like other chronic diseases.
There is urgent need of a new medication for ovarian cancer treatment because platinum-based chemotherapy has limited drug duration before the occurrence of intolerable side effects. Olaparib, together with other PARP inhibitors under development are all oral preparations which can be better tolerated and can have more long-term applications compared with those drugs used in conventional chemotherapy. Olaparib can prevent an enzyme which participate in cellular repair, and is suitable for patients with certain genetic mutations. The drug also has good prospects in the treatment of other cancers, opening up considerable market opportunities for olaparib.
In December 19, 2014, the FDA approved novel anti-cancer drug olaparib (Lynparza) for monotherapy to the patients of advanced ovarian cancer who has undergone at least 3 rounds of chemotherapy or patients of suspected BRCA mutations. At the same time, FDA approved the quantitation and classification of diagnostic kits for the detection of mutations in BRCA1 and BRCA2, BRACAnalysis CDx. Olaparib (Lynparza) is the first PARP inhibitor drugs which has been approved by FDA.
In February 2, 2015, the European Union Food and Drug Administration (EMA) also approved olaparib to enter into market in the 28 countries of European Union including Iceland, Liechtenstein and Norway. But the indications of EMA and FDA approved are slightly different; the former is for the BRCA gene mutation cases, and also for the maintenance therapy for patients of advanced epithelial ovarian cancer who has previously received platinum-containing chemotherapy drugs and exhibit response and subject to recurrence.